IMMUTEP LIMITED (IMM)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
![](/stocklogo/IMM.jpg)
IMM - IMMUTEP LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.03
Index: ALL-ORDS
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.03
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.29
02 Jul |
OPEN $0.32 |
HIGH $0.32 |
7,109,867 LOW $0.28 |
TARGET | |||||
|
OTHER COMPANIES IN THE SAME SECTOR | |||
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY22 Actual |
FY23 Actual |
FY24 Forecast |
FY25 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | - 4.4 | - 3.2 | xxx |
DPS (cps) | xxx | 0.0 | 0.0 | xxx |
EPS Growth | xxx | N/A | N/A | xxx |
DPS Growth | xxx | N/A | N/A | xxx |
PE Ratio | xxx | N/A | N/A | xxx |
Dividend Yield | xxx | N/A | 0.0% | xxx |
Div Pay Ratio(%) | xxx | N/A | N/A | xxx |
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -4.4 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 0.0 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 11.4 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -35.4 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | - |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -34.61 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -34.22 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -31.97 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -34.61 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -38.49 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -35.4 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 0 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 123 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 2.74 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 0.1 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | - |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 2 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 43 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 29 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
IMM STOCK CHART
![](/wp-content/uploads/2020/10/img-side-banner-stock-analysis.jpg)
FNArena News on IMM
1 |
Australian Broker Call *Extra* Edition – Jul 03, 202410:30 AM - Daily Market Reports |
2 |
Rudi’s View: Copper, Lithium, Retailers & TechnologyOneJun 27 2024 - Rudi's View |
3 |
Rudi’s View: Healthcare, Megatrends & FoMoJun 06 2024 - Rudi's View |
4 |
Rudi’s View: How To Benefit From EOFY SellingMay 30 2024 - Rudi's View |
5 |
Rudi’s View: Strategy Updates & Model PortfoliosMay 23 2024 - Rudi's View |
Latest Pharmaceuticals & Biotech/Lifesciences News
1 |
Dr Boreham’s Crucible: Radiopharm Theranostics11:00 AM - Small Caps |
2 |
Dr Boreham’s Crucible: Island TherapeuticsJun 17 2024 - Small Caps |
3 |
Dr Boreham’s Crucible: Amplia TherapeuticsJun 05 2024 - Small Caps |
4 |
Is The Long Wait For CSL About To End?May 30 2024 - Technicals |
5 |
Dr Boreham’s Crucible: InvionMay 13 2024 - Small Caps |
6 |
Dr Boreham’s Crucible: Race OncologyApr 09 2024 - Small Caps |
7 |
The Power Of New Weight-Loss DrugsApr 03 2024 - International |
8 |
Dr Boreham’s Crucible: Neuren PharmaceuticalsMar 11 2024 - Small Caps |
9 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
10 |
Transformational Trial Results For Neuren PharmaceuticalsDec 20 2023 - Small Caps |